SeekingAlpha · Jan 15, 2026
Ono Pharmaceutical Co., Ltd. (OPHLY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
2026-01-15. The following slide deck was published by Ono Pharmaceutical Co., Ltd.
OP
OTC · OPHLY
Ono Pharmaceutical Co., Ltd.
Healthcare · Drug Manufacturers - General
$5.00
Down-$0.01 (-0.20%)
Updated Aug 17, 2026, 12:54 PM
SID Score
5.3/10
Composite research score
Smart Money
46/100
Neutral
- Market cap
- 6.56B
- P/E ratio
- 21.09
- Dividend yield
- 3.61%
- 52-week range
- — – —
- Volume
- 1K
- Avg. volume
- 100.8K
Price performance
OPHLY price history
1M range · 0 trading sessions · Daily adjusted prices
OPHLY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest OPHLY news
The latest Smart Investors Daily articles mentioning OPHLY.
Stock researchCompany · Overview
OPHLY research
Overview
Company profile and research snapshot.
Company profile
ONO PHARM CO UNSP/ADR
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
SeekingAlpha · Jan 14, 2026
Ono Pharmaceutical Co., Ltd. (OPHLY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ono Pharmaceutical Co., Ltd. (OPHLY) 44th Annual J.P.
Yahoo · Jan 7, 2026
Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical
Amsterdam, the Netherlands, January 7, 2026 – Scenic Biotech, a pioneer in the field of modifier therapies for severe diseases, today announced a license and research agreement with Ono Pharmaceutical Co., Ltd. to utilize Scenic’s Cell-Seq platform for the discovery of novel therapeutic targets. “This collaboration with Ono Pharmaceutical represents another strong validation of our platform’s ability to uncover new disease biology and identify novel targets for rare and common indications,” said
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
